Case report: five-year experience of AKT inhibition with miransertib (MK-7075) in an individual with Proteus syndrome
{{output}}
Proteus syndrome is a rare overgrowth disorder caused by postzygotic activating variants in AKT1 Individuals may develop a range of skin, bone, and soft tissue overgrowth leading to functional impairment and disfigurement. Therapy for this disorder is limited ... ...
